Search MGNX
MACROGENICS INC
Nasdaq · CIK 1125345
Last close3.58
Daily change-0.02 (-0.56%)
10 Years gain-87.90%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
MGNX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
39.1Momentum
100.0Acceleration
60.0Confidence
76.0Annual Revenue15
Quarterly Revenue58
Annual CFO12
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.1 / 25
Quality17.5 / 25
Capital Efficiency4.0 / 20
Balance Sheet6.0 / 15
Shareholder Economics6.5 / 10
Forward Indicators5.0 / 5
Signals
Operating leverageOperating margin improved by 15.877 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Low interest coverage · HIGHInterest coverage is -5.3525x.
ROIC declining · MEDIUMROIC declined by 1318.1275 percentage points.
Key Metrics
Revenue Growth TTM-7.29%OK
Revenue CAGR 3Y-0.54%OK
Gross Marginn/aMISSING
Operating Margin-53.92%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-1,404.69%OK
Incremental Operating Margin 3Y260.77%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y1%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $149.50M | $149.50M | -$72.84M | -$81.04M | -$82.95M | 100% | -48.72% | -55.49% | n/a | 63.16M |
| 2025 FY Dec 31, 2024 | $149.96M | $149.12M | -$110.58M | -$68.37M | -$72.08M | 99.44% | -73.74% | -48.06% | n/a | 62.62M |
| 2025 FY Dec 31, 2023 | $58.75M | $58.13M | -$168.24M | -$78.21M | -$79.97M | 98.95% | -286.38% | -136.12% | -313.53% | 61.93M |
| 2024 FY Dec 31, 2022 | $151.94M | $148.59M | -$121.42M | -$86.96M | -$90.58M | 97.79% | -79.91% | -59.62% | -128.51% | 61.43M |
| 2023 FY Dec 31, 2021 | $77.45M | $74.80M | -$202.80M | -$143.83M | -$150.03M | 96.58% | -261.85% | -193.72% | -138.77% | 59.94M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $133.32M | sum latest 4 fiscal quarters Revenue | OK | 0001125345-26-000056, 0001125345-25-000108 |
| Revenue Growth TTM | -7.29% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001125345-26-000056, 0001125345-25-000108 |
| Revenue CAGR 3Y | -0.54% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001125345-26-000017 |
| Revenue CAGR 5Y | 7.35% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001125345-26-000017 |
| Gross Profit CAGR 3Y | 0.2% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001125345-26-000017 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001125345-26-000056, 0001125345-25-000108 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Margin | -53.92% | Operating Income / Revenue | OK | 0001125345-26-000056, 0001125345-25-000108 |
| ROIC | -1,404.69% | NOPAT / Average Invested Capital | OK | 0001125345-26-000056, 0001125345-25-000108 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001125345-26-000056 |
| Interest Coverage | -5.35x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 2.96x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $2.10 | Revenue / Diluted Shares | OK | 0001125345-26-000056, 0001125345-25-000108 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |